CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma

Cancer Research

Volumn 60, Issue 11, 2000, Pages 3013-3018

  Chen, Shaohua ^a   Caragine, Theresa ^a   Cheung, Nai Kong V ^b   Tomlinson, Stephen ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; MALE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT SYSTEM PROTEINS; DNA, COMPLEMENTARY; FLOW CYTOMETRY; HUMANS; IMMUNITY, NATURAL; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; RATS; RATS, NUDE; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0034214210     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kinders, R. J., Jones, T., Root, R., Bruce, C., Murchison, H., Corey, M., Williams, L., Enfield, D., and Hass, G. M. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin. Cancer Res., 4: 2511-2520, 1998.
2. Spendlove, I., Li, L., Carmichael, J., and Durrant, L. G. Decay-accelerating factor (CD55): a target for cancer vaccines. Cancer Res., 59: 2282-2286, 1999.
3. Maio, M., Brasoveanu, L. I., Coral, S., Sigalotti, L., Lamaj, E., Gasparollo, A., Visintin, A., Altomonte, M., and Fonsatti, E. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and immunotherapy of human malignancies. Int. J. Oncol., 13: 305-318, 1998.
4. Gorter, A., and Meri, S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today. 20: 576-582, 1999.
5. Yu, J., Caragine, T., Chen, S., Morgan, B. P., Frey, A. F., and Tomlinson, S. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin. Exp. Immunol., 115: 13-18, 1999.
6. Yu, J., Dong, S., Rushmere, N. K., Morgan, B. P., Abagyan, R., and Tomlinson, S. Mapping the regions of the complement inhibitor CD59 responsible for its species selectivity. Biochemistry, 36: 9423-9428, 1997.
7. Seya, T., Hara, T., Matsumoto, M., and Akedo, H. Quantitative analysis of membrane cofactor protein (MCP) of complement. J. Immunol., 145: 238-245, 1990.
8. Kinoshita, T., Medof, M. E., Silber, R., and Nussenzweig, V. Distribution of decay-accelerating factor in peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med., 162: 75-92, 1985.
9. Cheung, N-K. V., Saavinen, U. M., Neely, J. E., Landmeier, B., Donovan, D., and Coocia, P. F. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res., 45: 2642-2650, 1985.
10. Yu, J., Abagyan, R. A., Dong, S., Gilbert, A., Nussenzweig, V., and Tomlinson, S. Mapping the active site of CD59. J. Exp. Med., 185: 745-753, 1997.
11. Helfand, S. C., Hank, J. A., Gan, J., and Sondel, P. M. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Cell. Immunol., 167: 99-107, 1996.
12. Rushmere, N. K., Tomlinson, S., and Morgan, B. P. Expression of rat CD59: functional analysis confirms lack of species specificity and reveals that glycosylation is not required for function. Immunology, 90: 640-646, 1997.
13. Chen, S., Caragine, T., Cheung, N. K. V., and Tomlinson, S. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. Am. J. Pathol., 156: 1085-1091, 2000.
14. Wilson, A. P. Preparation of tumor cell lines. In: G. Gallagher, R. C. Rees, and C. W. Reynolds (eds.), Tumor Immunology: A Practical Approach, pp. 1-14. Oxford, United Kingdom: Oxford University Press, 1993.
15. Saarinen, U. M., Coccia, P. F., Gerson, S. L., Pelley, R., and Cheung, N. K. V. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res., 45: 499-503, 1985.
16. Mason, J. C., Yarwood, H., Sugars, K., Morgan, B. P., Davies, K. A., and Haskard, D. O. Induction of decay accelerating factor by cytokines or the membrane attack complex protects vascular endothelial cells against complement deposition. Blood, 94: 1673-1682, 1999.
17. Bjorge, L., Jensen, T. S., and Matre, R. Characterization of the complement regulatory proteins decay accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol. Immunother., 42: 185-192, 1996.
18. Varsano, S., Rashkovsky, L., Shapiro, H., and Radney, J. Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines. Am. J. Respir. Cell MoI. Biol., 19: 522-529, 1998.
19. Cosio, F. G., Shibata, T., Rovin, B. H., and Birmingham, D. J. Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. Kidney Int., 46: 986-992, 1994.
20. Berger, M., and Medof, M. E. Increased expression of complement decay accelerating factor during activation of human neutrophils. J. Clin. Invest., 79: 214-220, 1987.
21. Bjorge, L., Jensen, T. S., Ulvestad, E., Vedeler, C. A., and Matre, R. The influence of tumour necrosis factor-α, interleukin-1β and interferon-γ on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scand. J. Immunol., 41: 350-356, 1995.
22. Korty, P. E., Brando, C., and Shevach, E. M. CD59 functions as a signal-transducing molecule for human T cell activation. J. Immunol., 146: 4092-4098, 1991.
23. Hahn, W. C., Menu, E., Bothwell, A. L., Sims, P. J., and Bierer, B. E. Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59, Science (Washington DC), 256: 1805-1807, 1992.
24. Deckert, M., Kubar, J., Zoccola, D., Bernard-Pomier, G., Angelisova, P., Horejsi, V., and Bernard, A. CD59 molecule: a second ligand for CD2 in T cell adhesion. Eur. J. Immunol., 22: 2943-2947, 1992.
25. Morgan, B. P., Van den Berg, C. W., Davies, E. V., Hallett, M. B., and Horejsi, V. Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur. J. Immunol., 23: 2841-2850, 1993.
26. 2+-signalling. J. Cell. Biol., 131: 669-677, 1995.
27. Ong, G. L., and Mattes, M. J. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Methods, 125: 147-158, 1989.
28. Ish, C., Ong, G. L., Desai, N., and Mattes, M. J. The specificity of alternative complement pathway-mediated lysis of erythrocytes: a survey of complement and target cells from 25 species. Scand. J. Immunol., 38: 113-122, 1993.